Cite
The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
MLA
Jiang, Xie-Yuan, et al. “The Safety and Immunogenicity of a Recombinant Five-Antigen Staphylococcus Aureus Vaccine among Patients Undergoing Elective Surgery for Closed Fractures: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Clinical Trial.” Vaccine, vol. 41, no. 38, Aug. 2023, pp. 5562–71. EBSCOhost, https://doi.org/10.1016/j.vaccine.2023.07.047.
APA
Jiang, X.-Y., Gong, M.-Q., Zhang, H.-J., Peng, A.-Q., Xie, Z., Sun, D., Liu, L., Zhou, S.-Q., Chen, H., Yang, X.-F., Song, J.-F., Yu, B., Jiang, Q., Ma, X., Gu, J., Yang, F., Zeng, H., & Zou, Q.-M. (2023). The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial. Vaccine, 41(38), 5562–5571. https://doi.org/10.1016/j.vaccine.2023.07.047
Chicago
Jiang, Xie-Yuan, Mao-Qi Gong, Hua-Jie Zhang, A-Qin Peng, Zhao Xie, Dong Sun, Lie Liu, et al. 2023. “The Safety and Immunogenicity of a Recombinant Five-Antigen Staphylococcus Aureus Vaccine among Patients Undergoing Elective Surgery for Closed Fractures: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Clinical Trial.” Vaccine 41 (38): 5562–71. doi:10.1016/j.vaccine.2023.07.047.